

Herve Puy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8790272/publications.pdf>

Version: 2024-02-01

148
papers

7,484
citations

61984

43
h-index

60623

81
g-index

157
all docs

157
docs citations

157
times ranked

6691
citing authors

#	ARTICLE	IF	CITATIONS
1	Porphyrias. Lancet, The, 2010, 375, 924-937.	13.7	644
2	Gene Therapy in a Patient with Sickle Cell Disease. New England Journal of Medicine, 2017, 376, 848-855.	27.0	567
3	Gene Therapy in Patients with Transfusion-Dependent $\hat{1}^2$ -Thalassemia. New England Journal of Medicine, 2018, 378, 1479-1493.	27.0	525
4	C-Terminal Deletions in the ALAS2 Gene Lead to Gain of Function and Cause X-linked Dominant Protoporphyrinemia without Anemia or Iron Overload. American Journal of Human Genetics, 2008, 83, 408-414.	6.2	246
5	The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nature Genetics, 2002, 30, 27-28.	21.4	237
6	Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. Journal of Hepatology, 2015, 62, 848-854.	3.7	228
7	Erythropoietic protoporphyria. Orphanet Journal of Rare Diseases, 2009, 4, 19.	2.7	178
8	Contribution of a Common Single-Nucleotide Polymorphism to the Genetic Predisposition for Erythropoietic Protoporphyrinemia. American Journal of Human Genetics, 2006, 78, 2-14.	6.2	164
9	Inheritance in Erythropoietic Protoporphyrinemia: A Common Wild-Type Ferrochelatase Allelic Variant With Low Expression Accounts for Clinical Manifestation. Blood, 1999, 93, 2105-2110.	1.4	140
10	Molecular Epidemiology and Diagnosis of PBG Deaminase Gene Defects in Acute Intermittent Porphyria. American Journal of Human Genetics, 1997, 60, 1373-1383.	6.2	139
11	Porphyrias: A 2015 update. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 412-425.	1.5	132
12	Systematic Analysis of Molecular Defects in the Ferrochelatase Gene from Patients with Erythropoietic Protoporphyrinemia. American Journal of Human Genetics, 1998, 62, 1341-1352.	6.2	128
13	ABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis. Nature Genetics, 2012, 44, 170-173.	21.4	127
14	Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. Journal of Hepatology, 2000, 32, 933-939.	3.7	124
15	Sequential regulation of ferroportin expression after erythrophagocytosis in murine macrophages: early mRNA induction by haem, followed by iron-dependent protein expression. Biochemical Journal, 2008, 411, 123-131.	3.7	120
16	Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. Journal of Internal Medicine, 1997, 242, 213-217.	6.0	110
17	Iron Regulatory Proteins Secure Mitochondrial Iron Sufficiency and Function. Cell Metabolism, 2010, 12, 194-201.	16.2	110
18	Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. Nature Genetics, 2012, 44, 174-177.	21.4	105

#	ARTICLE	IF	CITATIONS
19	Variegate Porphyria in Western Europe: Identification of PPOX Gene Mutations in 104 Families, Extent of Allelic Heterogeneity, and Absence of Correlation between Phenotype and Type of Mutation. <i>American Journal of Human Genetics</i> , 1999, 65, 984-994.	6.2	100
20	High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. <i>Kidney International</i> , 2015, 88, 386-395.	5.2	84
21	ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. <i>Blood</i> , 2011, 118, 1443-1451.	1.4	80
22	Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. <i>Intensive Care Medicine</i> , 2010, 36, 1044-1048.	8.2	79
23	Heterozygous Mutations in BMP6 Pro-peptide Lead to Inappropriate Hepcidin Synthesis and Moderate Iron Overload in Humans. <i>Gastroenterology</i> , 2016, 150, 672-683.e4.	1.3	73
24	From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria. <i>Human Molecular Genetics</i> , 2018, 27, 1164-1173.	2.9	73
25	Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. <i>British Journal of Dermatology</i> , 2012, 167, 901-913.	1.5	71
26	Fecal calprotectin in inflammatory bowel diseases: update and perspectives. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 474-483.	2.3	70
27	Mutation in human <i>CLPX</i> elevates levels of δ -aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8045-E8052.	7.1	69
28	Human hereditary hepatic porphyrias. <i>Clinica Chimica Acta</i> , 2002, 325, 17-37.	1.1	66
29	A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. <i>British Journal of Dermatology</i> , 2012, 167, 888-900.	1.5	66
30	Characterization of Mutations in the CPO Gene in British Patients Demonstrates Absence of Genotype-Phenotype Correlation and Identifies Relationship between Hereditary Coproporphyrin and Harderoporphyria. <i>American Journal of Human Genetics</i> , 2001, 68, 1130-1138.	6.2	62
31	Iron Regulatory Protein 1 Sustains Mitochondrial Iron Loading and Function in Frataxin Deficiency. <i>Cell Metabolism</i> , 2015, 21, 311-323.	16.2	61
32	Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. <i>Blood</i> , 2007, 109, 811-818.	1.4	58
33	Hepcidin regulates intrarenal iron handling at the distal nephron. <i>Kidney International</i> , 2013, 84, 756-766.	5.2	58
34	Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins. <i>Clinica Chimica Acta</i> , 1995, 238, 163-168.	1.1	56
35	Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. <i>Human Mutation</i> , 2011, 32, 590-597.	2.5	56
36	A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i> -mutated myelodysplastic syndrome. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	55

#	ARTICLE	IF	CITATIONS
37	Mutations in the protoporphyrinogen oxidase gene in patients with variegate porphyria. <i>Human Molecular Genetics</i> , 1996, 5, 407-410.	2.9	54
38	Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks. <i>Life Sciences</i> , 1993, 53, 621-627.	4.3	52
39	Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. <i>Biomedicine and Pharmacotherapy</i> , 2005, 59, 20-24.	5.6	52
40	Acute intermittent porphyria causes hepatic mitochondrial energetic failure in a mouse model. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 51, 93-101.	2.8	51
41	Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. <i>Hepatology</i> , 1998, 27, 848-852.	7.3	49
42	Molecular characterization of homozygous variegate porphyria. <i>Human Molecular Genetics</i> , 1998, 7, 1921-1925.	2.9	49
43	A Variant of Peptide Transporter 2 Predicts the Severity of Porphyria-Associated Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1924-1932.	6.1	46
44	Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyria or erythropoietic harderoporphyria. <i>Human Molecular Genetics</i> , 2005, 14, 3089-3098.	2.9	44
45	Regulation of globin-heme balance in Diamond-Blackfan anemia by HSP70/GATA1. <i>Blood</i> , 2019, 133, 1358-1370.	1.4	44
46	Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome. <i>PLoS ONE</i> , 2017, 12, e0172147.	2.5	44
47	LC-MS/MS method for hepcidin-25 measurement in human and mouse serum: clinical and research implications in iron disorders. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1557-67.	2.3	43
48	Porphyria and kidney diseases. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 191-197.	2.9	43
49	Hepcidin as a Major Component of Renal Antibacterial Defenses against Uropathogenic <i>Escherichia coli</i> . <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 835-846.	6.1	42
50	Modulation of penetrance by the wild-type allele in dominantly inherited erythropoietic protoporphyria and acute hepatic porphyrias. <i>Human Genetics</i> , 2004, 114, 256-262.	3.8	40
51	Increased delta aminolevulinic acid and decreased pineal melatonin production. A common event in acute porphyria studies in the rat.. <i>Journal of Clinical Investigation</i> , 1996, 97, 104-110.	8.2	40
52	Influence of Age and Gender on the Clinical Expression of Acute Intermittent Porphyria Based on Molecular Study of Porphobilinogen Deaminase Gene Among Swiss Patients. <i>Molecular Medicine</i> , 2001, 7, 535-542.	4.4	39
53	Protoporphyrin Retention in Hepatocytes and Kupffer Cells Prevents Sclerosing Cholangitis in Erythropoietic Protoporphyria Mouse Model. <i>Gastroenterology</i> , 2011, 141, 1509-1519.e3.	1.3	39
54	Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP). <i>Human Molecular Genetics</i> , 2013, 22, 1280-1288.	2.9	39

#	ARTICLE	IF	CITATIONS
55	Iron deficiency diagnosed using hepcidin on critical care discharge is an independent risk factor for death and poor quality of life at one year: an observational prospective study on 1161 patients. <i>Critical Care</i> , 2018, 22, 314.	5.8	39
56	Molecular Characterization of Homozygous Variegate Porphyruria. <i>Human Molecular Genetics</i> , 1998, 7, 1921-1925.	2.9	37
57	Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites. <i>Blood</i> , 2015, 125, 534-541.	1.4	37
58	Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up. <i>European Journal of Heart Failure</i> , 2017, 19, 1075-1076.	7.1	37
59	Protoporphyrinogen Oxidase: Complete Genomic Sequence and Polymorphisms in the Human Gene. <i>Biochemical and Biophysical Research Communications</i> , 1996, 226, 226-230.	2.1	36
60	Iron metabolism in patients with anorexia nervosa: elevated serum hepcidin concentrations in the absence of inflammation. <i>American Journal of Clinical Nutrition</i> , 2012, 95, 548-554.	4.7	36
61	Antisense Oligonucleotide-Based Therapy in Human Erythropoietic Protoporphyruria. <i>American Journal of Human Genetics</i> , 2014, 94, 611-617.	6.2	34
62	Mitochondrial energetic defects in muscle and brain of a <i>Hmbs</i> ^{Δ/Δ} mouse model of acute intermittent porphyria. <i>Human Molecular Genetics</i> , 2015, 24, 5015-5023.	2.9	34
63	Porphobilinogen deaminase gene structure and molecular defects. <i>Journal of Bioenergetics and Biomembranes</i> , 1995, 27, 197-205.	2.3	33
64	Acute Hepatic Porphyrurias and Primary Liver Cancer. <i>New England Journal of Medicine</i> , 1998, 338, 1853-1854.	27.0	33
65	A mouse model provides evidence that genetic background modulates anemia and liver injury in erythropoietic protoporphyria. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, G1208-G1216.	3.4	32
66	Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 236-241.	1.1	32
67	Review: Molecular pathogenesis of hepatic acute porphyrias. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 1046-1052.	2.8	31
68	Exon 1 donor splice site mutations in the porphobilinogen deaminase gene in the non-erythroid variant form of acute intermittent porphyria. <i>Human Genetics</i> , 1998, 103, 570-575.	3.8	29
69	Role of two nutritional hepatic markers (insulin-like growth factor 1 and transthyretin) in the clinical assessment and follow-up of acute intermittent porphyria patients. <i>Journal of Internal Medicine</i> , 2009, 266, 277-285.	6.0	28
70	Genetic Study of Variation in Normal Mouse Iron Homeostasis Reveals Ceruloplasmin as an HFE-Hemochromatosis Modifier Gene. <i>Gastroenterology</i> , 2007, 132, 679-686.	1.3	26
71	Loss of heterozygosity on 10q and mutational status of PTEN and BMP1A in colorectal primary tumours and metastases. <i>British Journal of Cancer</i> , 2004, 90, 1230-1234.	6.4	25
72	Regulation and tissue-specific expression of δ -aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 190-197.	1.1	25

#	ARTICLE	IF	CITATIONS
73	Pro-oxidant effect of ALA is implicated in mitochondrial dysfunction of HepG2 cells. <i>Biochimie</i> , 2014, 106, 157-166.	2.6	24
74	Renal Function Decline Under Therapy With Small Interfering RNA Silencing ALAS1 for Acute Intermittent Porphyrin. <i>Kidney International Reports</i> , 2021, 6, 1904-1911.	0.8	24
75	Identification of a Prevalent Nonsense Mutation (W283X) and Two Novel Mutations in the Porphobilinogen Deaminase Gene of Swiss Patients with Acute Intermittent Porphyrin. <i>Human Heredity</i> , 2000, 50, 247-250.	0.8	23
76	Acute hepatic and erythropoietic porphyrias: from ALA synthases 1 and 2 to new molecular bases and treatments. <i>Current Opinion in Hematology</i> , 2017, 24, 198-207.	2.5	23
77	Hepatocellular carcinoma without cirrhosis: think acute hepatic porphyrias and vice versa. <i>Journal of Internal Medicine</i> , 2011, 269, 521-524.	6.0	22
78	Erythroid-Progenitor-Targeted Gene Therapy Using Bifunctional TFR1 Ligand-Peptides in Human Erythropoietic Protoporphyrin. <i>American Journal of Human Genetics</i> , 2019, 104, 341-347.	6.2	22
79	Urinary Metabolic Fingerprint of Acute Intermittent Porphyrin Analyzed by ¹ H NMR Spectroscopy. <i>Analytical Chemistry</i> , 2014, 86, 2166-2174.	6.5	21
80	Three novel mutations in the coproporphyrinogen oxidase gene. <i>Human Mutation</i> , 1997, 9, 78-80.	2.5	20
81	Heme and acute inflammation. Role in vivo of heme in the hepatic expression of positive acute-phase reactants in rats. <i>FEBS Journal</i> , 1999, 261, 190-196.	0.2	20
82	Molecular abnormalities of coproporphyrinogen oxidase in patients with hereditary coproporphyrin. <i>Journal of Bioenergetics and Biomembranes</i> , 1995, 27, 215-219.	2.3	19
83	Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?. <i>EuPA Open Proteomics</i> , 2014, 3, 60-67.	2.5	19
84	GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in Human congenital sideroblastic anemia. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 342-351.	1.1	19
85	Porphobilinogen deaminase gene in African and Afro-Caribbean ethnic groups: mutations causing acute intermittent porphyria and specific intragenic polymorphisms. <i>Human Genetics</i> , 2000, 107, 150-159.	3.8	18
86	Human Erythroid 5-Aminolevulinic Synthase Mutations Associated with X-Linked Protoporphyrin Disrupt the Conformational Equilibrium and Enhance Product Release. <i>Biochemistry</i> , 2015, 54, 5617-5631.	2.5	18
87	Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease. <i>Haematologica</i> , 2018, 103, 587-596.	3.5	18
88	Molecular analysis of porphobilinogen (PBG) deaminase gene mutations in acute intermittent porphyria: first study in patients of Slavic origin. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1997, 57, 217-224.	1.2	17
89	Ancestral Founder of Mutation W283X in the Porphobilinogen Deaminase Gene among Acute Intermittent Porphyrin Patients. <i>Human Heredity</i> , 2002, 54, 69-81.	0.8	17
90	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2019, 104, 497-504.	3.5	17

#	ARTICLE	IF	CITATIONS
91	Nitric oxide synthase inhibition and the induction of cytochrome P-450 affect heme oxygenase-1 messenger RNA expression after partial hepatectomy and acute inflammation in rats. <i>Critical Care Medicine</i> , 1998, 26, 1683-1689.	0.9	17
92	Givosiran in acute intermittent porphyria: A personalized medicine approach. <i>Molecular Genetics and Metabolism</i> , 2022, 135, 206-214.	1.1	17
93	Evaluation of mutation screening by heteroduplex analysis in acute intermittent porphyria: comparison with denaturing gradient gel electrophoresis. <i>Clinica Chimica Acta</i> , 1999, 279, 133-143.	1.1	16
94	International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. <i>Genetics in Medicine</i> , 2019, 21, 2605-2613.	2.4	16
95	Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria. <i>Blood</i> , 2020, 136, 2457-2468.	1.4	16
96	Analytical correlation between plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in patients presenting with dyspnea. <i>Clinical Biochemistry</i> , 2004, 37, 933-936.	1.9	15
97	Detection of Four Novel Mutations in the Porphobilinogen Deaminase Gene in French Caucasian Patients with Acute Intermittent Porphyria. <i>Human Heredity</i> , 1996, 46, 177-180.	0.8	14
98	A molecular, enzymatic and clinical study in a family with hereditary coproporphyrinuria. <i>Journal of Inherited Metabolic Disease</i> , 2002, 25, 279-286.	3.6	14
99	Does IV Iron Induce Plasma Oxidative Stress in Critically Ill Patients? A Comparison With Healthy Volunteers*. <i>Critical Care Medicine</i> , 2016, 44, 521-530.	0.9	13
100	Hemolytic anemia repressed hepcidin level without hepatocyte iron overload: lesson from GÄ¼nther disease model. <i>Haematologica</i> , 2017, 102, 260-270.	3.5	13
101	High urinary ferritin reflects myoglobin iron evacuation in DMD patients. <i>Neuromuscular Disorders</i> , 2018, 28, 564-571.	0.6	13
102	Phlebotomy as an efficient long-term treatment of congenital erythropoietic porphyria. <i>Haematologica</i> , 2021, 106, 913-917.	3.5	13
103	Isoniazid inhibits human erythroid 5-aminolevulinic acid synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 428-439.	3.8	12
104	Mutations in the Ferrochelatase Gene of Four Spanish Patients with Erythropoietic Protoporphyrinuria. <i>Journal of Investigative Dermatology</i> , 1998, 111, 406-409.	0.7	11
105	A homoallelic <i>FECH</i> mutation in a patient with both erythropoietic protoporphyria and palmar keratoderma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1349-1353.	2.4	11
106	Late-Onset X-Linked Dominant Protoporphyrinuria: An Etiology of Photosensitivity in the Elderly. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1688-1690.	0.7	11
107	Extrahepatic hepcidin production: The intriguing outcomes of recent years. <i>World Journal of Clinical Cases</i> , 2019, 7, 1926-1936.	0.8	11
108	Iron, Heme Synthesis and Erythropoietic Porphyrias: A Complex Interplay. <i>Metabolites</i> , 2021, 11, 798.	2.9	11

#	ARTICLE	IF	CITATIONS
109	Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). <i>Cellular and Molecular Biology</i> , 2002, 48, 33-41.	0.9	11
110	Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases. <i>Nutrients</i> , 2022, 14, 1039.	4.1	11
111	New mutations of the hydroxymethylbilane synthase gene in German patients with acute intermittent porphyria. <i>Molecular and Cellular Probes</i> , 1999, 13, 443-447.	2.1	10
112	Melatonin and Environmental Lighting Regulate ALA-DES Gene Expression and So Porphyrin Biosynthesis in the Rat Harderian Gland. <i>Chronobiology International</i> , 2008, 25, 851-867.	2.0	10
113	A mutation in the iron-responsive element of <i>hALAS2</i> is a modifier of disease severity in a patient suffering from <i>hCLPX1</i> ; associated erythropoietic protoporphyria. <i>Haematologica</i> , 2021, 106, 2030-2033.	3.5	10
114	PXR-ALAS1: A key regulatory pathway in liver toxicity induced by isoniazid-rifampicin antituberculosis treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 439-441.	1.5	9
115	Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2017, 36, 391-396.	1.4	9
116	Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 309-313.	1.1	9
117	Comprehensive cytochrome P450 CYP1A2 gene analysis in French caucasian patients with familial and sporadic porphyria cutanea tarda. <i>British Journal of Dermatology</i> , 2012, 166, 425-429.	1.5	8
118	Thyroid hormone extraction by plasma exchange: a study of extraction rate. <i>Biomedicine and Pharmacotherapy</i> , 1992, 46, 413-417.	5.6	7
119	Acute Intermittent Porphyria: From Clinical to Molecular Aspects. , 2003, , 23-41.		7
120	An Uncommon Option for Surviving Bariatric Surgery: Regaining Weight!. <i>American Journal of Medicine</i> , 2012, 125, e1-e2.	1.5	7
121	Urinary metabolic profiling of asymptomatic acute intermittent porphyria using a rule-mining-based algorithm. <i>Metabolomics</i> , 2018, 14, 10.	3.0	7
122	Genetic background influences hepcidin response to iron imbalance in a mouse model of hemolytic anemia (Congenital erythropoietic porphyria). <i>Biochemical and Biophysical Research Communications</i> , 2019, 520, 297-303.	2.1	7
123	Kidney transplantation improves the clinical outcomes of Acute Intermittent Porphyria. <i>Molecular Genetics and Metabolism</i> , 2020, 131, 259-266.	1.1	7
124	Iloprost Use in Patients with Persistent Intestinal Ischemia Unsuitable for Revascularization. <i>Annals of Vascular Surgery</i> , 2017, 42, 128-135.	0.9	6
125	Analytical comparison of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill patients. <i>Bioanalysis</i> , 2021, 13, 1029-1035.	1.5	6
126	Identification of novel UROS mutations in a patient with congenital erythropoietic porphyria and efficient treatment by phlebotomy. <i>Molecular Genetics and Metabolism Reports</i> , 2021, 27, 100722.	1.1	5

#	ARTICLE	IF	CITATIONS
127	Biochemical compared to molecular diagnosis in acute intermittent porphyria. <i>Journal of Inherited Metabolic Disease</i> , 2006, 29, 157-161.	3.6	4
128	GNPAT polymorphism rs11558492 is not associated with increased severity in a large cohort of HFE p.Cys282Tyr homozygous patients. <i>Hepatology</i> , 2017, 65, 1069-1071.	7.3	4
129	Functional erythropoietin-hepcidin axis in recombinant human erythropoietin independent haemodialysis patients. <i>Nephrology</i> , 2019, 24, 751-757.	1.6	4
130	Systemic Administered mRNA as Therapy for Metabolic Diseases. <i>Trends in Molecular Medicine</i> , 2019, 25, 3-5.	6.7	4
131	Hepcidin and Iron Deficiency in Women One Year after Sleeve Gastrectomy: A Prospective Cohort Study. <i>Nutrients</i> , 2021, 13, 2516.	4.1	4
132	Update from the Hgb-205 Phase 1/2 Clinical Study of Lentiglobin Gene Therapy: Sustained Clinical Benefit in Severe Hemoglobinopathies. <i>Blood</i> , 2016, 128, 2311-2311.	1.4	4
133	TSPO2 translocates 5-aminolevulinic acid into human erythroleukemia cells. <i>Biology of the Cell</i> , 2020, 112, 113-126.	2.0	3
134	Immunological specificity of monoclonal antibodies to <i>Chlamydia psittaci</i> ovine abortion strain. <i>Immunology Letters</i> , 1990, 23, 217-221.	2.5	2
135	Heme Biosynthesis and Pathophysiology of Porphyrins. <i>Handbook of Porphyrin Science</i> , 2013, , 89-118.	0.8	2
136	Reply. <i>Gastroenterology</i> , 2016, 151, 771-772.	1.3	2
137	ABCB6 Polymorphisms are not Overly Represented in Patients with Porphyria. <i>Blood Advances</i> , 2021, , .	5.2	2
138	Acute porphyric attack mimicking HIV-associated progressive polyradiculoneuropathy. <i>Médecine Et Maladies Infectieuses</i> , 2011, 41, 441-443.	5.0	1
139	Characterization and origin of heme precursors in amniotic fluid: lessons from normal and pathological pregnancies. <i>Pediatric Research</i> , 2018, 84, 80-84.	2.3	1
140	Crosstalk between Acidosis and Iron Metabolism: Data from In Vivo Studies. <i>Metabolites</i> , 2022, 12, 89.	2.9	1
141	Heme-arginate in the treatment of acute porphyrias : effect on iron metabolism and heme catabolites. <i>Journal of Hepatology</i> , 2001, 34, 197-198.	3.7	0
142	Chediak-Steinbrinck-Higashi Syndrome. , 2009, , 314-314.		0
143	Epistasis in iron metabolism: complex interactions between Cp, Mon1a, and Slc40a1 loci and tissue iron in mice. <i>Mammalian Genome</i> , 2013, 24, 427-438.	2.2	0
144	P442 N terminal brain natriuretic peptide versus brain natriuretic peptide for the diagnosis of heart failure in patients over 75 years old. <i>European Heart Journal</i> , 2003, 24, 62.	2.2	0

#	ARTICLE	IF	CITATIONS
145	Les porphyries héréditaires : anomalies du métabolisme de l'hème. Bulletin De L'Academie Nationale De Medecine, 2014, 198, 1069-1093.	0.0	0
146	Erythropoietic Protoporphyrin Red Blood Cells Are Resistant to the Growth of Malarial Parasites. Blood, 2014, 124, 2670-2670.	1.4	0
147	Assessment of Cardiac Iron Overload in Chronically Transfused Patients with Thalassemia, Sickle Cell Anemia, and Myelodysplastic Syndromes. Blood, 2015, 126, 2151-2151.	1.4	0
148	A Dominant Mutation in Mitochondrial Unfoldase CLPX Results in Erythropoietic Protoporphyrin. Blood, 2016, 128, 77-77.	1.4	0